Who’s Afraid of the Big, Bad Bioterrorist?

The recent dustup about The H5N1 Bird Flu Plague That Will Kill Us All (not) has brought the topic of “bioterrorism” into the media spotlight again. This is an issue I’ve been following for several years, and during that time I’ve come to a conclusion that’s pretty much the opposite of everything we’ve been told: biodefense is largely a waste of money.

Let’s start with the current definition of the problem. The US government has prepared a list of “select agents” that are considered potential biological weapons. Researchers who work on these agents have to get special clearances, and an entire multi-billion-dollar industry of defense contractors has sprung up to help the nation prepare for a terrorist attack using one of these weapons. I have two problems with this list.

First, several of the listed “agents” shouldn’t be treated as biological threats at all; they are chemical weapons. Botulinum toxin and ricin, for example, both appear on the list, but an attack with either of these toxins would bear no resemblance to a biological outbreak. Their toxicity is generally acute, so the first responders to such attacks would be police and firefighters, whereas the first responders to a true biological attack would be physicians and nurses. Toxins don’t reproduce or spread, so the response would be about containing and decontaminating the scene, not tracking contacts and cases. The list conflates two completely different types of threats. But perhaps that’s just a technical gripe.

The second problem is much more serious. Eliminating the toxins, we’re left with a list of infectious bacteria and viruses. With a single exception, these organisms are probably near-useless as weapons, and history proves it.

There have been at least three well-documented military-style deployments of infectious agents from the list, plus one deployment of an agent that’s not on the list. I’m focusing entirely on the modern era, by the way. There are historical reports of armies catapulting plague-ridden corpses over city walls and conquistadors trying to inoculate blankets with Variola (smallpox), but it’s not clear those “attacks” were effective. Those diseases tended to spread like, well, plagues, so there’s no telling whether the targets really caught the diseases from the bodies and blankets, or simply picked them up through casual contact with their enemies.

Of the four modern biowarfare incidents, two have been fatal. The first was the 1979 Sverdlovsk anthrax incident, which killed an estimated 100 people. In that case, a Soviet-built biological weapons lab accidentally released a large plume of weaponized Bacillus anthracis (anthrax) over a major city. Soviet authorities tried to blame the resulting fatalities on “bad meat,” but in the 1990s Western investigators were finally able to piece together the real story. The second fatal incident also involved anthrax from a government-run lab: the 2001 “Amerithrax” attacks. That time, a rogue employee (or perhaps employees) of the government’s main bioweapons lab sent weaponized, powdered anthrax through the US postal service. Five people died.

That gives us a grand total of around 105 deaths, entirely from agents that were grown and weaponized in officially-sanctioned and funded bioweapons research labs. Remember that.

Terrorist groups have also deployed biological weapons twice, and these cases are very instructive. The first was the 1984 Rajneeshee bioterror attack, in which members of a cult in Oregon inoculated restaurant salad bars with Salmonella bacteria (an agent that’s not on the “select” list). 751 people got sick, but nobody died. Public health authorities handled it as a conventional foodborne Salmonella outbreak, identified the sources and contained them. Nobody even would have known it was a deliberate attack if a member of the cult hadn’t come forward afterward with a confession. Lesson: our existing public health infrastructure was entirely adequate to respond to a major bioterrorist attack.

The second genuine bioterrorist attack took place in 1993. Members of the Aum Shinrikyo cult successfully isolated and grew a large stock of anthrax bacteria, then sprayed it as an aerosol from the roof of a building in downtown Tokyo. The cult was well-financed, and had many highly educated members, so this release over the world’s largest city really represented a worst-case scenario.

Nobody got sick or died. From the cult’s perspective, it was a complete and utter failure. Again, the only reason we even found out about it was a post-hoc confession. Aum members later demonstrated their lab skills by producing Sarin nerve gas, with far deadlier results. Lesson: one of the top “select agents” is extremely hard to grow and deploy even for relatively skilled non-state groups. It’s a really crappy bioterrorist weapon.

Taken together, these events point to an uncomfortable but inevitable conclusion: our biodefense industry is a far greater threat to us than any actual bioterrorists.

For comparison, Timothy McVeigh pulled a Ryder rental truck full of ammonium nitrate and fuel oil (both very easily obtained) in front of a Federal building, and killed 168 people. The 9/11 hijackers killed almost 3,000 people and blew up the headquarters of the United States military, using box cutters and basic flight training. In 2000, a couple of guys in an inflatable boat full of explosives totaled an American battleship. I could go on, but hopefully you get the point: conventional weapons are orders of magnitude more effective for terrorism than biological ones.

Astute readers may have noticed that I mentioned a single exception on the select agent list. I’m talking about smallpox, and the reason it’s an exception is interesting: it’s a good weapon only because we successfully eradicated it.

Had the World Health Organization focused on controlling smallpox instead of eradicating it, there would have been continued pressure to develop improved vaccines, and likely continued vaccination. That’s the pattern now with poliovirus, which has been incorporated into one of the standard combination vaccines that kids receive.

But because the WHO focused on eradicating smallpox instead, they stuck with the primitive vaccine originally developed in the 18th century by Edward Jenner. Once the world was certified smallpox-free, vaccination stopped. Now, nearly everyone born in the past forty years or so is susceptible to this highly contagious, highly lethal virus.

Smallpox would still be a very poor choice for bioterrorism, but for a different reason than the rest of the select agents. A terrorist group that actually got ahold of it could probably culture it and deploy it without much trouble – in many ways it would be easier to work with than anthrax. However, there is no question who would be hit hardest by a new global pandemic of smallpox: the poor countries. The US already stockpiles hundreds of millions of doses of smallpox vaccine and antivirals. Once an outbreak was identified, it would be straightforward to track and stop, at least in the developed world. The people who would suffer and die would be precisely the ones most terrorist groups are trying to represent. Military types call that “blowback,” and it’s a very bad thing.

So what should we do? First, stop panicking. Terrorist groups have repeatedly said they want biological weapons, but that’s either propaganda or fantasy. The groups that have actually pursued such weapons have found that they’re a complete waste of resources. However, the fear of bioweapons has caused governments around the world – particularly in the US – to spend billions of dollars on technologies they will never need. Spending the same money on our ailing public health system would have been a much better investment.

We should keep stockpiling vaccines and antivirals against smallpox, against the tiny but nonzero probability that some terrorist might actually have the contradictory combination of resourcefulness and stupidity necessary to get ahold of this virus, then deploy it. We should probably continue researching improved smallpox vaccines, too, if only because the work could yield useful insights about other, more relevant viruses. But most importantly, we should drastically reduce the size of our current “biodefense” efforts, which have unambiguously proven themselves to be more harmful than beneficial. Hiring and training more people to work with select agents is the problem, not the solution.

Posted in Uncategorized | Tagged , , , | Leave a comment

Open Access vs. Local Politics

Someone just asked me what I thought of Michael Eisen’s op-ed piece that came out in the New York Times a couple of weeks ago. Eisen wrote about a new bill in Congress that would roll back a NIH policy requiring NIH-funded researchers to submit copies of their publications to the National Library of Medicine’s publicly accessible web site. As Eisen explains:

But a bill introduced in the House of Representatives last month threatens to cripple this site. The Research Works Act would forbid the N.I.H. to require, as it now does, that its grantees provide copies of the papers they publish in peer-reviewed journals to the library. If the bill passes, to read the results of federally funded research, most Americans would have to buy access to individual articles at a cost of $15 or $30 apiece. In other words, taxpayers who already paid for the research would have to pay again to read the results.

This is the latest salvo in a continuing battle between the publishers of biomedical research journals like Cell, Science and The New England Journal of Medicine, which are seeking to protect a valuable franchise, and researchers, librarians and patient advocacy groups seeking to provide open access to publicly funded research.

The bill is backed by the powerful Association of American Publishers and sponsored by Representatives Carolyn B. Maloney, Democrat of New York, and Darrell Issa, a Republican from California. The publishers argue that they add value to the finished product, and that requiring them to provide free access to journal articles within a year of publication denies them their fair compensation. After all, they claim, while the research may be publicly funded, the journals are not.

I work for some of those journals, and don’t agree with the policy their lobbyists are promoting here. That said, I’m not entirely persuaded by the open access argument Eisen promotes. I’ve described some of my concerns on this blog already. Briefly, I don’t think the open access movement is really about making research “free.” It’s mainly haggling over price and billing.

The public absolutely should have direct access to the results from taxpayer-financed research, without having to pay a second time. By charging exorbitant per-article access fees and subscription rates, subscriber-supported journals are putting profit over public interest. Of course most of them are private corporations, so they’re supposed to act selfishly. That’s why we need a regulation that requires them to release these papers to the public within a reasonable time frame.

That said, the business model Eisen supports isn’t truly free. Open access journals such as the PLoS family of publications invariably charge a hefty “page fee” for researchers to publish their work. They also make a considerable amount of money from advertising. This has led to a booming industry of “open access” journals, some of which are little more than rebranded vanity presses. Don’t let the charitable-sounding description fool you; open access journals, even the really good ones, are still very much about profit.

Not that there’s anything wrong with that. I make my living from those profits. Indeed, while Eisen and other open access proponents often point out that peer reviewers work for free, they seldom mention the rest of the hardworking staff required to publish a credible journal. At journals such as Science and Cell, for example, someone with the title “Research Editor” has to receive the deluge of submitted manuscripts, triage them, distribute them to appropriate peer reviewers, evaluate the reviewers’ comments, and ultimately decide what to accept. Good research editors are not easy to find, and they absolutely don’t (and shouldn’t be expected to) work for free. For journals that also have news sections, as all of the really big ones now do, there are also news editors and writers like me. If we want to continue to have that added value in research publications – and the evidence is that everyone does – then we have to figure out how to pay for it. There’s also the cost of page design, archiving, and for journals that still have a paper edition, printing and distribution.

The real distinction between subscriber-supported and open access journals, then, is not whether they are in business to make a profit, but who pays and how much. In open access, the researchers pay through their taxpayer-funded grants and the advertising costs of the equipment and services they buy. In the subscription model, readers pay. So the taxpayers ultimately pick up the tab in both cases, just by different mechanisms.

Back when journals were only available on paper, and anyone could get access to them through the library system, the public could read the research they’d paid for at no cost. It just took awhile through inter-library loan. Now we expect everything to be available online, so the NIH open access policy forces the papers to be released that way. As I said, I think that’s appropriate. Yes, someone could still go to the library and ultimately get access to all of the papers, but in the 21st century we shouldn’t require that.

I think the solution is for journals that are currently subscriber supported to move to a business model that’s more like open access. The NIH policy is a good nudge in that direction, as it mandates public release of the papers, but only after a six-month grace period. While the subscriber-supported journals can still charge for immediate access, the policy puts them on notice that they’d better come up with a new plan for the long term. As PLoS and others have demonstrated, that doesn’t have to mean working for free.

So why did Maloney and Issa push a bill that would derail this evolution in science publishing? Well, Maloney’s Congressional district includes the US corporate headquarters of mega-publisher Elsevier, and Issa’s district is adjacent to two other Elsevier offices. Just sayin’.

Posted in Uncategorized | Tagged , , , | 5 Comments

TWiV 167: It starts with a cough

The complete TWiVome deconstructs the movie Contagion.

Posted in TWiV, Uncategorized | Leave a comment

The Day the Science Died

This afternoon, a coalition of influenza virologists released a statement saying that they are voluntarily suspending research on H5N1 “bird flu” for 60 days. This was in response to the Category 5 hype storm that has accompanied the publication of two papers about this virus. My previous post on this topic (and links therein) provides a quick review for those who haven’t been following this story.

I’m of two minds about the new moratorium. As a scientist, I think it’s moronic. H5N1 flu is biologically interesting, and could become a major public health concern if it ever manages to sustain human-to-human transmission. Though its lethality has probably been vastly overstated, there’s no doubt that it is capable of killing at least some people, under some circumstances. The demonstration that it’s possible for H5N1 to adapt to a mammalian host, even one that diverged from the primate lineage many millions of years ago, shows that we need to step up H5N1 research, not halt it.

However, the biodefense industry’s recent push to whip up fear has completely distorted the public’s perception of this issue. Millions of nonscientists are now convinced that the recent virus transmission work was dangerous, perhaps even foolhardy, and that terrorist groups could easily take advantage of the new findings to kill millions. None of that is even remotely true. Unfortunately, people who are in a panic aren’t capable of rationally evaluating the nuances, so the scientists who’ve been trying to defend ongoing H5N1 work are at a disadvantage. Saying they’ll suspend that work is the only reasonable public relations strategy at this point.

Around the same time the moratorium was announced, a partially overlapping group of virologists sent an open letter to the National Science Advisory Board for Biosecurity (NSABB), giving that board a thump on the head. It was the NSABB that started this whole circus, by calling for the new H5N1 publications to be partially censored. In the open letter, the virologists argue that this censorship is unjustifiably hindering scientific progress. They were apparently too polite to say that deliberately omitting data from a publication in response to a nebulous, entirely theoretical “security risk” is antithetical to the whole scientific enterprise, so I’ll do it for them.

The moratorium should help bolster public confidence in the scientists’ ability to address this issue themselves, while the letter to the NSABB lays the groundwork for a productive debate based on reason rather than fear. Hopefully, in a couple of months everyone will be able to calm down and get back to work.

Posted in Uncategorized | Tagged , , , , | 7 Comments

Oh, So That’s Where Those Were

Don’t you love it when you finally get around to cleaning out an old closet, and you find all sorts of stuff you forgot you had? Apparently that happens to museum curators, too, as the BBC reports:

Dr Falcon-Lang, who is based in the department of earth sciences at Royal Holloway, University of London, spotted some drawers in a cabinet marked “unregistered fossil plants”.

“Inside the drawer were hundreds of beautiful glass slides made by polishing fossil plants into thin translucent sheets,” Dr Falcon-Lang explained. “This process allows them to be studied under the microscope. Almost the first slide I picked up was labelled ‘C. Darwin Esq’.”

The item turned out to be a piece of fossil wood collected by Darwin during his famous Voyage of the Beagle in 1834. This was the expedition on which he first started to develop his theory of evolution.

JD Hooker

J.D. Hooker: great botanist, not-so-great closet organizer. Image courtesy BGS.

It seems that J.D. Hooker, a botanist and Darwin’s collaborator, received a bunch of fossilized plant specimens from his friend during the historic voyage. Hooker cut thin sections of the fossils and stored them carefully in drawers, but then forgot to record them in the British Geological Survey’s index. So there they sat, unnoticed, for over 170 years.

Fortunately, the specimens have now been found, and Falcon-Lang and his colleagues have documented and digitized the whole collection. You can see all of the material online at the BGS’s site.

Now I’m going to go tidy up a bit in the basement.

Posted in Uncategorized | Tagged , , , | Leave a comment

TWiV 166: Breaking and entering

Vincent, Dickson, Rich, and Alan review cell proteins essential for entry of hepatitis C, Ebola, and measles viruses.

Links for this episode:

Posted in TWiV, Uncategorized | Leave a comment

TWiV 165: The email zone

Vincent, Dickson, Rich, and Alan answer listener questions about XMRV, cytomegalovirus, latency, shingles vaccine, myxomavirus and rabbits, and more.

Posted in TWiV, Uncategorized | Comments Off

Welcome to Wesort World Headquarters

Wayne sent this note through the contact form:

I sailed a Wesort my family owned back in the 70′s. I was a sloop rigged sailing rowboat designed and built locally in the Severn River region during the 60′s. Mine had the number 127, but I’m not sure how many were made. It was made of plywood with a flat bottom and wooden mast with a closet dowel for a boom. It was rather slow, but since it was a sloop it gave a more complete sailing experience than the faster and smaller Penquins that used to race together in Severn regattas.

Thanks, Wayne. I assume you found my post about Wesort boats through a Google search. That led me to do a search for ‘wesort boat’ myself, revealing that I’m apparently the internet’s leading authority on these small craft. And I know next to nothing about them.

Nonetheless, I want to welcome other Wesort fans to pop by. All of us here at Wesort World Headquarters will be happy to hear from you.

Posted in Uncategorized | Tagged , , , | Comments Off

Business? Warning? Cry for Help?

Business? Warning? Cry for Help?

Business? Warning? Cry for Help?

Posted in Uncategorized | Tagged , , , | Comments Off

TWiV Beats Placebo!

This is a screenshot from the iTunes store today (in Podcasts > Science and Medicine > Medicine):

TWiV Beats Placebo

TWiV Beats Placebo

So our year-in-review episode is five places better than placebo. Be sure to take it weekly from now on.

Posted in Uncategorized | Tagged , , , | 1 Comment